Astragaloside IV confronts amyloid-beta-induced astrocyte senescence via hsp90aa1
Journal of Applied Biomedicine · 2024
DOI: 10.32725/jab.2024.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Biomedicine, 2024. Verfasst von Xia Yan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Xiangyang Hospital of Traditional Chinese Medicine (Xiangyang Institute of Traditional Chinese Medicine), Institute of Traditional Chinese Medicine, …. Hauptthemen laut MEDLINE: Saponins, Triterpenes, Astrocytes, Cellular Senescence. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National TCM Specialty, Xiangyang Key Science and Technology Program Project.
Abstract (Originalsprache)
Cell senescence is intensively related to aging and neurodegenerative diseases. This study aimed to explore the effect and targets of Astragaloside IV against amyloid-beta-induced astrocyte senescence. Oligomerized amyloid-beta was prepared to culture with human astrocytes. The effects of Astragaloside IV were assessed based on SA-β-gal staining analysis, senescence markers (p53, p16INK4, and p21WAF1), neurotrophic growth factor levels (qRT-PCR), and cell proliferation (CCK-8 kit). The targets for Astragaloside IV were predicted, and hsp90aa1 protein was verified using molecular docking. After hsp90aa1 overexpression, the effects of Astragaloside IV on amyloid-beta-induced astrocytes were assessed. Treatment of human amyloid-beta-induced astrocytes with Astragaloside IV can decrease the percentage of SA-β-gal positive cells, downregulate the p53, p16INK4, and p21WAF1 levels, and increase the levels of neurotrophic growth factors (IGF-1 and NGF mRNA) and cell proliferation. Based on target prediction, hsp90aa1 was found to be a potential target of Astragaloside IV. Moreover, cellular experiments demonstrated that exogenously enhanced expression of hsp90aa1 overexpression suppressed the protective effect of Astragaloside IV on amyloid-beta-induced human astrocytes. The results presented here demonstrate that Astragaloside IV could confront amyloid-beta-induced astrocyte senescence via hsp90aa1, possibly opening new therapeutic avenues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xiangyang Hospital of Traditional Chinese Medicine (Xiangyang Institute of Traditional Chinese Medicine), Institute of Traditional Chinese Medicine, Xiangyang 441000, China.
- Foshan Hospital of Traditional Chinese Medicine, Foshan 528000, China.
- Xiangyang Hospital of Traditional Chinese Medicine (Xiangyang Institute of Traditional Chinese Medicine), Department of Anesthesiology, Xiangyang 441000, China.
Förderung
- National TCM Specialty
- Xiangyang Key Science and Technology Program Project
Zitieren
APA
Yan, X., Zeng, R., & Cao, Y. (2024). Astragaloside IV confronts amyloid-beta-induced astrocyte senescence via hsp90aa1. Journal of Applied Biomedicine. https://doi.org/10.32725/jab.2024.015
Vancouver
Yan X, Zeng R, Cao Y. Astragaloside IV confronts amyloid-beta-induced astrocyte senescence via hsp90aa1. Journal of Applied Biomedicine. 2024. doi:10.32725/jab.2024.015
BibTeX
@article{Yan2024,
author = {Yan, Xia and Zeng, Rongxiang and Cao, Yajun},
title = {Astragaloside IV confronts amyloid-beta-induced astrocyte senescence via hsp90aa1},
journal = {Journal of Applied Biomedicine},
year = {2024},
doi = {10.32725/jab.2024.015}
}
EUVIMED